摘要

【摘要】
目的 探讨鲁拉西酮与利培酮治疗精神分裂症疗效及对代谢指标的影响差异。

方法 纳入2024年1月-2025年6月136例精神分裂症患者，回顾性分析病历资料，66例采用利培酮治疗，设对照组，70例采用鲁拉西酮治疗，设观察组。比较两组患者治疗前后阳性与阴性症状评分、血脂代谢指标以及副反应量表（treatment emergent symptom scale，TESS）。

结果 治疗后2组各项症状评分均显著低于治疗前，但治疗后观察组阴性症状评分显著低于对照组，（P＜0.05），其余两项差异不显著（P>0.05）；治疗后对照组空腹血糖、总胆固醇、低密度脂蛋白醇均升高，（P＜0.05），观察组治疗前后差异不显著（P>0.05），治疗后观察组各项指标均显著低于对照组，（P<0.05）；治疗2周、4周、8周时观察组TESS评分均显著低于对照组，（P<0.05）。

结论 鲁拉西酮与利培酮治疗精神分裂症均能显著减轻阳性症状，但鲁拉西酮对阴性症状改善效果更佳，对脂糖代谢影响更轻，耐受性更好。

关键词：【关键词】鲁拉西酮；利培酮；精神分裂症；疗效；代谢指标

ABSTRACT

[Abstract]
Objective To explore the differences in therapeutic efficacy and impact on metabolic indicators between lurasidone and risperidone in the treatment of schizophrenia.

Methods A total of 136 patients with schizophrenia from January 2024 to June 2025, A retrospective analysis was conducted on the medical records. Sixty-six cases were treated with risperidone and set as the control group, while 70 cases were treated with loracidone and set as the observation group. The positive and negative symptom scores, lipid metabolism indicators, and treatment emergent symptom scale (TESS) between two groups of patients before and after treatment were compared.

Results After treatment, the symptom scores of both groups were significantly lower than before treatment, but the negative symptom scores of the observation group were significantly lower than those of the control group after treatment (P<0.05). The other two differences were not significant (P>0.05). After treatment, the fasting blood glucose, total cholesterol, and low-density lipoprotein cholesterol in the control group all increased (P<0.05). There was no significant difference in the observation group before and after treatment (P>0.05). After treatment, all indicators in the observation group were significantly lower than those in the control group (P<0.05). At 2, 4, and 8 weeks of treatment, the TESS scores of the observation group were significantly lower than those of the control group (P<0.05).

Conclusion   Both lurasidone and risperidone can significantly alleviate positive symptoms in the treatment of schizophrenia, but lurasidone has a better effect on improving negative symptoms, has a lighter impact on lipid metabolism, and has better tolerance.

Key words: Key words Lurasidone; Risperidone; Schizophrenia; Therapeutic Effect; Metabolic Indicators